At a glance
ClinicalIndex Comparison RecordN/ACompleted· 612 enrolled
Drug / intervention
VI +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparing the Safety and Efficacy of Virtual Ileostomy Versus Diverting Ileostomy in Patients Underwent Total Mesorectal Excision for Rectal Cancer: a Propensity-matched Study
In Brief
An observational study evaluating VI and DI for Rectal Cancer. Completed, enrolled 612 participants across 1 site.
Detailed Summary
This study aimed at comparing the Comprehensive Complication Index (CCI), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with virtual ileostomy versus conventional divertingileostomy after total mesorectal excision for rectal cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedAug 2023
Primary CompletionOct 2024
Study CompletionOct 2024
TodayJul 2026
First PostedAug 14, 2023
Enrollment StartJan 1, 2023
Primary CompletionOct 10, 2024
Study CompletionOct 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.9 years ago
Interventions
VIprocedure
Laparoscopic or robotic surgery with virtual ileostomy
DIprocedure
Laparoscopic or robotic surgery with virtual ileostomy